TGFB2 and cancer: A role for TGF-β2 in supporting the invasive potential of 6.5/cancer cells was next evaluated using Trabedersen, a specific TGF-β2-targeting antisense oligonucleotide currently evaluated in clinical trials38–40, and SB431542, a selective TGF-βRI inhibitor.